<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02629562</url>
  </required_header>
  <id_info>
    <org_study_id>B12019-101</org_study_id>
    <nct_id>NCT02629562</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects</brief_title>
  <official_title>Single-dose, Randomised, Double-blind, Two-stage, Two-way Crossover Pharmacokinetic and Pharmacodynamic Evaluation of a Biosimilar Pegfilgrastim (B12019) Versus the Reference Product Neulasta® in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cinfa Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cinfa Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-centre, double-blind, randomised, 2-way cross-over study to investigate the PK and PD
      of B12019 as compared to Neulasta® administered as a single subcutaneous (s.c.) dose in
      healthy male subjects. B12019 or Neulasta will be administered by s.c. injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameter AUC0-last</measure>
    <time_frame>6 weeks</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter Cmax</measure>
    <time_frame>6 weeks</time_frame>
    <description>Maximum observed drug concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD parameter ANC</measure>
    <time_frame>6 weeks</time_frame>
    <description>AUEC0-last</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Clinical Pharmacology</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>first dosing: single dose of 6mg of B12019 administered subcutaneously, second dosing: single dose of 6mg of Neulasta administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>first dosing: single dose of 6mg of Neulasta administered subcutaneously, second dosing: single dose of 6mg of B12019 administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>B12019 and Neulasta</intervention_name>
    <description>GCSF, Growth Colony Stimulating Factor</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects

          -  Age ≥18 and ≤55 years

          -  BMI 22.0 - 28.0 kg/m2

          -  Non-smokers for at least 6 months prior to study start

          -  General good health, based on a comprehensive medical history and physical examination

          -  Adequate organ function and normal laboratory values (unless the investigator
             considers an abnormality to be clinically not relevant)

          -  Negative hepatitis B surface antigen (HBsAg), hepatitis C antibody and human
             immunodeficiency virus (HIV) tests at screening

          -  Signed informed consent

        Exclusion Criteria:

          -  Known hypersensitivity to Escherichia coli derived proteins, pegfilgrastim, filgrastim
             or any other component of B12019 or Neulasta®

          -  Previous exposure to filgrastim or pegfilgrastim

          -  History of drug or alcohol abuse

          -  Blood donations in the past 3 months prior to study start, or bone marrow or stem cell
             donor in the past 12 months (first dose)

          -  Medical history of haematological disease, including sickle cell disorders

          -  Recent infection (within 1 week prior to first dose)

          -  Relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory,
             skin, haematological, endocrine, inflammatory or neurological diseases, that in the
             opinion of the investigator may interfere with the aim of the study

          -  Participation in an interventional or Phase I study in the last 3 months or is current
             a follow-up visit schedule for any study, or has participation in more than three
             studies of experimental drug products in the past 12 months prior to screening

          -  Subjects with ANC values outside the normal laboratory range at screening

          -  Use of prescription or over-the-counter drugs including vitamins within 4 weeks of
             first dosing

          -  Abnormalities in ECG

          -  Signs of dermatitis or skin abnormalities affecting the administration area and
             surroundings

          -  History of cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lissy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuvisan GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2015</study_first_submitted>
  <study_first_submitted_qc>December 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2015</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

